SCAI Cardiogenic Shock

Question 1

Intro

Answer 1

treatment of acute myocardial infarction (MI) and heart failure (HF) has advanced exponentially over the last 50 years. One of the greatest advances has been the routine use of immediate percutaneous coronary intervention (Primary PCI) for ST segment elevation MI (STEMI) which has reduced mortality and subsequent HF substantially

cardiogenic shock (CS) may occur prior to or following reperfusion. Even those who survive acute intervention may later develop CS and the overall 30-day mortality for patients with CS in association with MI is approximately 40–50

SHOCK (SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK)

Question 2

The SHOCK tria

Answer 2

The SHOCK trial was conducted when the only percutaneous form of cardiopulmonary support was the intra-aortic balloon pump (IABP). Since then, multiple devices (e.g., left atrial to femoral artery bypass devices [TandemHeart left ventricular assist device, LivaNova, London, UK], axial left ventricular—aorta pumps [Impella, Abiomed, Danvers, MA]), as well as similar devices for right ventricular support and veno-arterial (VA) extracorporeal membrane oxygenation (ECMO) have been developed and studied in the setting of CS

Question 3

Table

Answer 3